572:
Schwartz, Steven D; Regillo, Carl D; Lam, Byron L; Eliott, Dean; Rosenfeld, Philip J; Gregori, Ninel Z; Hubschman, Jean-Pierre; Davis, Janet L; Heilwell, Gad; Spirn, Marc; Maguire, Joseph; Gay, Roger; Bateman, Jane; Ostrick, Rosaleen M; Morris, Debra; Vincent, Matthew; Anglade, Eddy; Del Priore,
528:
Schwartz, Steven D; Hubschman, Jean-Pierre; Heilwell, Gad; Franco-Cardenas, Valentina; Pan, Carolyn K; Ostrick, Rosaleen M; Mickunas, Edmund; Gay, Roger; Klimanskaya, Irina; Lanza, Robert (2012). "Embryonic stem cell trials for macular degeneration: A preliminary report".
676:
573:
Lucian V; Lanza, Robert (2015). "Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and
Stargardt's macular dystrophy: Follow-up of two open-label phase 1/2 studies".
385:
680:
144:. Upon Mr. Caldwell's death on December 13, 2010, Gary Rabin, a member of ACT's board of directors with experience in investment and capital raising, assumed the role of Chairman and CEO.
664:
335:
409:
506:
431:
762:
772:
189:
In July 2014, Ocata announced that Paul K. Wotton, previously of
Antares Pharma Inc (ATRS:NASDAQ CM), became President and Chief Executive Officer.
386:"Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries - Feb 10, 2016"
249:
In
November 2010 the FDA allowed Ocata to begin a Phase I/II human clinical trial to use its retinal pigment epithelium cell therapy to treat
726:
339:
641:
310:
417:
186:
to treat retinal diseases. A preliminary report of the trial published in 2012, and a follow-up article was published in
February 2015.
616:
167:. In 2008, for $ 250,000 plus royalties up to a total of $ 1 million, the company licensed its "ACTCellerate" technology to BioTime.
456:
272:
514:
75:
Stem cell therapies for macular degeneration (human safety trial started in 2010), retinis pigmentosa, glaucoma and corneal blindness
360:
17:
701:
435:
677:"Advanced Cell Technology Files IND with FDA for First Clinical Trial Using Embryonic Stem Cells to Treat Dry AMD"
777:
267:
175:
136:
Advanced Cell
Technology was formed in 1994 and was led from 2005 to late 2010 by William M. Caldwell IV,
192:
On August 27, 2014, Ocata announced a 1-100 reverse stock split of its common stock. Ocata was listed on
222:
103:
757:
210:
141:
314:
488:
475:"Press Release: ACTCellerate Technology Licensed to BioTime, Inc by Advanced Cell Technology"
156:
460:
230:
226:
218:
183:
8:
767:
126:
in
November 2014. In February 2016 Ocata was acquired by Astellas for $ 379 million USD.
292:
174:
On
November 22, 2010, the company announced that it had received approval from the U.S.
598:
554:
474:
586:
542:
590:
546:
250:
152:
111:
107:
582:
558:
538:
602:
148:
99:
65:
214:
179:
85:
262:
751:
727:"Advanced Cell Technology Receives FDA Clearance to Initiate Clinical Trials"
234:
47:
594:
550:
168:
705:
527:
642:"Ocata's $ 379M acquisition leaves many small investors disillusioned"
665:
Ocata
Therapeutics Approved for Listing on NASDAQ February 26, 2015
137:
160:
238:
193:
336:"Advanced Cell Technology Changes Name to Ocata Therapeutics"
457:"Bloomberg Longevity Economy Conference 2013 Panelist Bio"
164:
571:
233:
and represents a market size of $ 25–30 Billion in the
489:"New Method for Controversy Free Embryonic Stem Cells"
147:
In 2007 the company's Chief
Scientific Officer (CSO),
617:"Cynata appoints Paul K Wotton to Board of Directors"
507:"FDA approves second human embryonic stem cell trial"
253:, a form of inherited juvenile macular degeneration.
432:"Advanced Cell Technology Senior Executive Officers"
361:"Astellas to acquire Ocata Therapeutics for $ 379M"
749:
365:GEN - Genetic Engineering and Biotechnology News
338:. Ocata Therapeutics. 2014-11-14. Archived from
293:"Company seeks to test stem cells for blindness"
229:(Dry AMD). Dry AMD is the most common form of
763:Biotechnology companies of the United States
702:"ACT Seeks FDA Approval For Stem Cell Study"
213:application with the U.S. FDA for the first
114:. It was formed in 1994 as a company named
96:Astellas Institute for Regenerative Medicine
31:Astellas Institute for Regenerative Medicine
773:Biotechnology companies established in 1994
303:
434:. Advanced Cell Technology. Archived from
639:
273:Stem cells without embryonic destruction
204:
14:
750:
244:
116:Advanced Cell Technology, Incorporated
209:On November 30, 2010, Ocata filed an
390:Astellas Pharma US, Inc. | News Room
110:with a focus on diseases that cause
24:
640:Seiffert, Don (18 November 2015).
513:. 22 November 2010. Archived from
311:"Ocata website: Pipeline Overview"
178:(FDA) to initiate the first human
25:
789:
719:
694:
669:
658:
633:
609:
565:
521:
499:
481:
416:. 23 March 2010. Archived from
467:
449:
424:
402:
378:
353:
328:
285:
13:
1:
587:10.1016/S0140-6736(14)61376-3
543:10.1016/S0140-6736(12)60028-2
278:
268:Somatic cell nuclear transfer
263:Key stem cell research events
27:Subsidiary of Astellas Pharma
176:Food and Drug Administration
7:
256:
199:
10:
794:
223:retinal pigment epithelium
131:
104:Marlborough, Massachusetts
225:to treat Dry Age-Related
79:
71:
61:
53:
43:
35:
211:Investigational New Drug
122:), which was renamed to
18:Advanced Cell Technology
646:Boston Business Journal
621:www.biospectrumasia.com
151:, PhD, also founder of
142:Chief Executive Officer
778:Life sciences industry
517:on November 24, 2010.
157:regenerative medicine
155:left Ocata to join a
420:on October 18, 2010.
231:macular degeneration
227:Macular Degeneration
219:embryonic stem cells
205:Macular degeneration
184:embryonic stem cells
410:"Executive Profile"
245:Stargardt's disease
171:was appointed CSO.
108:stem cell therapies
98:is a subsidiary of
32:
196:in February 2015.
124:Ocata Therapeutics
30:
581:(9967): 509–516.
537:(9817): 713–720.
251:Stargardt disease
106:, US, developing
93:
92:
16:(Redirected from
785:
742:
741:
739:
737:
723:
717:
716:
714:
713:
704:. Archived from
698:
692:
691:
689:
688:
679:. Archived from
673:
667:
662:
656:
655:
653:
652:
637:
631:
630:
628:
627:
613:
607:
606:
569:
563:
562:
525:
519:
518:
503:
497:
496:
485:
479:
478:
471:
465:
464:
459:. Archived from
453:
447:
446:
444:
443:
428:
422:
421:
414:BusinessWeek.com
406:
400:
399:
397:
396:
382:
376:
375:
373:
372:
357:
351:
350:
348:
347:
332:
326:
325:
323:
322:
313:. Archived from
307:
301:
300:
289:
89:
88:
86:Official website
33:
29:
21:
793:
792:
788:
787:
786:
784:
783:
782:
758:Astellas Pharma
748:
747:
746:
745:
735:
733:
725:
724:
720:
711:
709:
700:
699:
695:
686:
684:
675:
674:
670:
663:
659:
650:
648:
638:
634:
625:
623:
615:
614:
610:
570:
566:
526:
522:
505:
504:
500:
487:
486:
482:
473:
472:
468:
455:
454:
450:
441:
439:
430:
429:
425:
408:
407:
403:
394:
392:
384:
383:
379:
370:
368:
359:
358:
354:
345:
343:
334:
333:
329:
320:
318:
309:
308:
304:
291:
290:
286:
281:
259:
247:
207:
202:
149:Michael D. West
134:
100:Astellas Pharma
84:
83:
66:Marlborough, MA
28:
23:
22:
15:
12:
11:
5:
791:
781:
780:
775:
770:
765:
760:
744:
743:
718:
693:
668:
657:
632:
608:
564:
520:
498:
495:. 9 July 2008.
480:
466:
463:on 2013-08-03.
448:
423:
401:
377:
352:
327:
302:
283:
282:
280:
277:
276:
275:
270:
265:
258:
255:
246:
243:
221:to regenerate
215:clinical trial
206:
203:
201:
198:
180:clinical trial
133:
130:
91:
90:
81:
77:
76:
73:
69:
68:
63:
59:
58:
55:
51:
50:
45:
41:
40:
37:
26:
9:
6:
4:
3:
2:
790:
779:
776:
774:
771:
769:
766:
764:
761:
759:
756:
755:
753:
732:
728:
722:
708:on 2010-12-13
707:
703:
697:
683:on 2010-12-05
682:
678:
672:
666:
661:
647:
643:
636:
622:
618:
612:
604:
600:
596:
592:
588:
584:
580:
576:
568:
560:
556:
552:
548:
544:
540:
536:
532:
524:
516:
512:
508:
502:
494:
493:Wired Science
490:
484:
476:
470:
462:
458:
452:
438:on 2014-07-20
437:
433:
427:
419:
415:
411:
405:
391:
387:
381:
366:
362:
356:
342:on 2015-04-02
341:
337:
331:
317:on 2015-01-09
316:
312:
306:
299:. 2009-11-25.
298:
294:
288:
284:
274:
271:
269:
266:
264:
261:
260:
254:
252:
242:
240:
236:
232:
228:
224:
220:
216:
212:
197:
195:
190:
187:
185:
181:
177:
172:
170:
166:
162:
158:
154:
150:
145:
143:
139:
129:
127:
125:
121:
117:
113:
109:
105:
101:
97:
87:
82:
78:
74:
70:
67:
64:
60:
56:
52:
49:
48:Biotechnology
46:
42:
38:
34:
19:
734:. Retrieved
731:Retina Today
730:
721:
710:. Retrieved
706:the original
696:
685:. Retrieved
681:the original
671:
660:
649:. Retrieved
645:
635:
624:. Retrieved
620:
611:
578:
574:
567:
534:
530:
523:
515:the original
510:
501:
492:
483:
469:
461:the original
451:
440:. Retrieved
436:the original
426:
418:the original
413:
404:
393:. Retrieved
389:
380:
369:. Retrieved
367:. 2015-11-10
364:
355:
344:. Retrieved
340:the original
330:
319:. Retrieved
315:the original
305:
296:
287:
248:
208:
191:
188:
173:
169:Robert Lanza
146:
135:
128:
123:
119:
115:
95:
94:
62:Headquarters
36:Company type
102:located in
768:Stem cells
752:Categories
712:2010-11-30
687:2010-11-30
651:2020-04-29
626:2020-04-29
575:The Lancet
531:The Lancet
442:2014-08-13
395:2020-04-29
371:2020-04-29
346:2015-04-25
321:2015-03-09
279:References
39:Subsidiary
112:blindness
595:25458728
551:22281388
257:See also
200:Research
138:Chairman
72:Products
44:Industry
736:5 April
559:2230787
511:CNN.com
297:Reuters
161:BioTime
132:History
80:Website
54:Founded
601:
593:
557:
549:
239:Europe
237:. and
217:using
194:NASDAQ
182:using
159:firm,
603:85799
599:S2CID
555:S2CID
153:Geron
738:2015
591:PMID
547:PMID
140:and
57:1994
583:doi
579:385
539:doi
535:379
235:U.S
165:CEO
163:as
120:ACT
754::
729:.
644:.
619:.
597:.
589:.
577:.
553:.
545:.
533:.
509:.
491:.
412:.
388:.
363:.
295:.
241:.
740:.
715:.
690:.
654:.
629:.
605:.
585::
561:.
541::
477:.
445:.
398:.
374:.
349:.
324:.
118:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.